71.17 USD
+0.24 (+0.34%)
71.1 USD
-0.07 (-0.1%)
We assign a fundamental rating of 4 out of 10 to TARS. TARS was compared to 191 industry peers in the Pharmaceuticals industry. While TARS seems to be doing ok healthwise, there are quite some concerns on its profitability. TARS is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- TARS had negative earnings in the past year.
- In the past year TARS has reported a negative cash flow from operations.
- TARS had negative earnings in each of the past 5 years.
- TARS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- TARS has a Return On Assets of -15.18%. This is in the better half of the industry: TARS outperforms 62.30% of its industry peers.
- Looking at the Return On Equity, with a value of -24.22%, TARS is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.18% | ||
| ROE | -24.22% | ||
| ROIC | N/A |
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- TARS has a better Gross Margin (93.26%) than 94.76% of its industry peers.
- In the last couple of years the Gross Margin of TARS has remained more or less at the same level.
- TARS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for TARS has been increased compared to 1 year ago.
- Compared to 5 years ago, TARS has more shares outstanding
- TARS has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 9.00 indicates that TARS is not in any danger for bankruptcy at the moment.
- TARS's Altman-Z score of 9.00 is amongst the best of the industry. TARS outperforms 81.15% of its industry peers.
- TARS has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
- TARS's Debt to Equity ratio of 0.22 is in line compared to the rest of the industry. TARS outperforms 44.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9 |
ROIC/WACCN/A
WACC9.54%
2.3 Liquidity
- TARS has a Current Ratio of 4.29. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of TARS (4.29) is better than 61.78% of its industry peers.
- TARS has a Quick Ratio of 4.25. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of TARS (4.25) is better than 63.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.29 | ||
| Quick Ratio | 4.25 |
3. Growth
3.1 Past
- TARS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.98%, which is quite impressive.
- TARS shows a strong growth in Revenue. In the last year, the Revenue has grown by 182.44%.
- TARS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.48% yearly.
EPS 1Y (TTM)46.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.82%
Revenue 1Y (TTM)182.44%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%146.68%
3.2 Future
- The Earnings Per Share is expected to grow by 36.25% on average over the next years. This is a very strong growth
- Based on estimates for the next years, TARS will show a very strong growth in Revenue. The Revenue will grow by 46.55% on average per year.
EPS Next Y51.69%
EPS Next 2Y60.48%
EPS Next 3Y50.14%
EPS Next 5Y36.25%
Revenue Next Year153.81%
Revenue Next 2Y97.38%
Revenue Next 3Y71.65%
Revenue Next 5Y46.55%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for TARS. In the last year negative earnings were reported.
- A Price/Forward Earnings ratio of 39.91 indicates a quite expensive valuation of TARS.
- 70.16% of the companies in the same industry are more expensive than TARS, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.30, TARS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 39.91 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as TARS's earnings are expected to grow with 50.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.48%
EPS Next 3Y50.14%
5. Dividend
5.1 Amount
- No dividends for TARS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
71.17
+0.24 (+0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-23 2026-02-23/amc
Inst Owners108.04%
Inst Owner Change-0.37%
Ins Owners3.09%
Ins Owner Change-1.29%
Market Cap3.02B
Revenue(TTM)366.10M
Net Income(TTM)-81.16M
Analysts86.25
Price Target88.63 (24.53%)
Short Float %11.47%
Short Ratio8.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.85%
Min EPS beat(2)-17.77%
Max EPS beat(2)16.07%
EPS beat(4)3
Avg EPS beat(4)8.3%
Min EPS beat(4)-17.77%
Max EPS beat(4)20.78%
EPS beat(8)7
Avg EPS beat(8)12.73%
EPS beat(12)10
Avg EPS beat(12)11.89%
EPS beat(16)13
Avg EPS beat(16)13.53%
Revenue beat(2)2
Avg Revenue beat(2)3.09%
Min Revenue beat(2)0.99%
Max Revenue beat(2)5.19%
Revenue beat(4)4
Avg Revenue beat(4)5.95%
Min Revenue beat(4)0.99%
Max Revenue beat(4)11.62%
Revenue beat(8)8
Avg Revenue beat(8)30.02%
Revenue beat(12)9
Avg Revenue beat(12)39.62%
Revenue beat(16)10
Avg Revenue beat(16)13.76%
PT rev (1m)1.92%
PT rev (3m)17.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.95%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.2%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)4.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 39.91 | ||
| P/S | 8.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.02 | ||
| P/tB | 9.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.02
EYN/A
EPS(NY)1.78
Fwd EY2.51%
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS8.62
BVpS7.89
TBVpS7.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.18% | ||
| ROE | -24.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.26% | ||
| FCFM | N/A |
ROA(3y)-36.36%
ROA(5y)-26.48%
ROE(3y)-50.88%
ROE(5y)-35.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.18%
GM growth 5YN/A
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 474.96% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.29 | ||
| Quick Ratio | 4.25 | ||
| Altman-Z | 9 |
F-Score5
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)439.33%
Cap/Depr(5y)393.66%
Cap/Sales(3y)12.37%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.82%
EPS Next Y51.69%
EPS Next 2Y60.48%
EPS Next 3Y50.14%
EPS Next 5Y36.25%
Revenue 1Y (TTM)182.44%
Revenue growth 3Y47.48%
Revenue growth 5YN/A
Sales Q2Q%146.68%
Revenue Next Year153.81%
Revenue Next 2Y97.38%
Revenue Next 3Y71.65%
Revenue Next 5Y46.55%
EBIT growth 1Y37.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.71%
EBIT Next 3Y59.8%
EBIT Next 5Y49.54%
FCF growth 1Y33.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.39%
OCF growth 3YN/A
OCF growth 5YN/A
TARSUS PHARMACEUTICALS INC / TARS FAQ
Can you provide the ChartMill fundamental rating for TARSUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to TARS.
What is the valuation status for TARS stock?
ChartMill assigns a valuation rating of 2 / 10 to TARSUS PHARMACEUTICALS INC (TARS). This can be considered as Overvalued.
Can you provide the profitability details for TARSUS PHARMACEUTICALS INC?
TARSUS PHARMACEUTICALS INC (TARS) has a profitability rating of 2 / 10.